Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21141927 | 0.82 | — | — | |
| SCHEMBL1958727 | 0.78 | KDM1A (0.40) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL9417434 | 0.78 | SMN1; SMN2 (0.41) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL6505659 | 0.78 | ALDH1A1 (0.41) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL2744386 | 0.78 | KDM1A (0.40) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL7004174 | 0.76 | KDM1A (0.39) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL10571360 | 0.75 | KDM1A (0.45) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL4721218 | 0.75 | HTT (0.49) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL9126435 | 0.75 | KDM1A (0.38) | KDM1ACA12CA1CA2CA9 | |
| SCHEMBL13451264 | 0.73 | TDP1 (0.47) | KDM1ASMN1; SMN2HPGDALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511327-B1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | LANOVA MEDICINES LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10882853-B2 | Tyrosine kinase inhibitor and application thereof | LaNova Medicines Limited (CN) | 2021-01-05 | — | — | US | disclosed |
| CN-107235896-B | Tyrosine kinase inhibitor and application thereof | 上海翔锦生物科技有限公司 | 2019-11-05 | — | — | CN | disclosed |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | SHANGHAI XIANGJIN BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3511327-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | Shanghai Xiangjin Biotechnology Co., Ltd (CN) | 2019-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882853-B2 | Tyrosine kinase inhibitor and application thereof | KDR, FLT1, FLT4 | KDM1A 1185/4885CA12 3650/4885CA1 3551/4885 |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | KDR, FLT1, MET | KDM1A 1227/4885CA12 3720/4885CA1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.